Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback